SK Bioscience COVID-19 Vaccine Heterologous Booster Shot Phase 3 Trial Plan Approved in Nepal

[Asia Economy Reporter Gong Byung-sun] SK Bioscience announced on the 4th that the Nepal health authorities have approved the Phase 3 clinical trial plan for the heterologous booster shot (additional vaccination with a different vaccine) of the COVID-19 vaccine 'GBP510'.

The Nepal Phase 3 clinical trial will be conducted by evaluating immunogenicity and safety when administering a third dose of GBP510 to healthy adults who have previously received two doses of an authorized COVID-19 vaccine.

GBP510 is the first domestically produced COVID-19 vaccine approved by the Korean Ministry of Food and Drug Safety at the end of June. It was jointly developed by the University of Washington School of Pharmacy and SK Bioscience using a recombinant protein antigen method. The domestic product name is 'Skycovione'.

SK Bioscience stated, "We expect to confirm the effect of enhancing the immune response, which decreases over time after the primary vaccination, through the booster shot, as well as sufficient safety."

This content was produced with the assistance of AI translation services.